RE: Question28 Feb 2021 22:04
10 x currennt share price = 5 billion mcap that is absolutly chicken feed with avactas potential over the next 3/5 + years
If the clinical trials perform we will be looking at 100 x mcap without any problems for starters imop
If the covid lft performs gold standard, putting avacta in the driving seat with heavy sales 2/3 years minimum
Solidifiying avacta as a testing giant most likely bringing out new tests for many other disease's/conditions
Setting us up nicely for a nice steady revenue from testing alone, that will putva big dent in the 5 billion mcap alone
What happens if the doxcurubicon trial goes to plan
Currently a 1 billion market, that could be double tripled
If we got 1/3 of that, on a drug thats been around 40/50 years, then how many years multiple would you use for that ? 5/10
All pie in the sky till proven, but if....IF it is proven then theres atleast another half dozen cancer drugs that would like the same treatment, 3 already lined up on possible sucess
So anyone thinking that 20/50 /200 + is a fantasy might need to do more reasearch unless they want to sell them selves short
Also i cant imagine As letting his company go for 5/10/20 billion hes not stupid, is it rampy know i dont think so lets see how she goes the next 3/5 years cause i aint going any whare gla
Sorry for the DYS